PUBLISHER: Grand View Research | PRODUCT CODE: 2067529
PUBLISHER: Grand View Research | PRODUCT CODE: 2067529
The global immune cell engineering market size was estimated at USD 4.19 billion in 2025 and is anticipated to reach USD 14.31 billion by 2033, growing at a CAGR of 17.3% from 2026 to 2033. This growth is driven by the increasing adoption of engineered immune cell therapies for cancer and autoimmune disease treatment, rising investments in cell and gene therapy research, and continuous advancements in technologies such as CRISPR and CAR-T cell engineering.
Advancements in Gene-Editing and Cell Therapy Technologies
Advancements in gene-editing and cell therapy technologies are driving the immune cell engineering market by enabling more precise and personalized immunotherapies. Tools such as CRISPR-Cas9, TALENs, and improved viral and non-viral delivery systems enhance the genetic modification of immune cells, such as T cells and NK cells, thereby improving their ability to target cancer cells. In addition, innovations in CAR-T and TCR-T therapies are increasing treatment efficacy, reducing off-target effects, and expanding applications to solid tumors and autoimmune diseases.
Global Immune Cell Engineering Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global immune cell engineering market report based on cell type, product, disease indication, end-use, and region: